Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H21NO2 |
Molecular Weight | 271.3541 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CC[C@]23[C@@H]4CCC[C@H]2[C@H]1CC5=C3C(O4)=C(O)C=C5
InChI
InChIKey=LNNWVNGFPYWNQE-GMIGKAJZSA-N
InChI=1S/C17H21NO2/c1-18-8-7-17-11-3-2-4-14(17)20-16-13(19)6-5-10(15(16)17)9-12(11)18/h5-6,11-12,14,19H,2-4,7-9H2,1H3/t11-,12+,14-,17+/m0/s1
Desomorphine is the common name for 4,5--epoxy-17- methylmorphinan-3-ol or dihydrodesoxymorphine-D. It is an opioid analogue and morphine derivative in which the 6-hydroxyl group and the double bond at carbons 7 and 8 of morphine are reduced. Desomorphine can cross the blood–brain barrier, binding to opioid receptors, similar to the pharmacokinetic distribution of all phenanthrene-structured alkaloids. Taking Desomorphine causes euphoria as well as sedative and analgesic relief. In addition to its faster onset than other powerful painkillers drugs such as morphine, desomorphine also initiates less sedative effects and seems to have favorable postoperative results, such as reduced need for catheterization, less dizziness, and decreased vomiting incidence. In comparison with Morphine, Desomorphine is faster reduced. It follows that it has to be taken it more frequently to get the same effects. Furthermore, it causes side effects such as respiratory and gastrointestinal problems and increased blood pressure. In addition, Desomorphine’s withdrawal symptoms are up to three times longer than Morphine’s. This leads to the conclusion that Desomorphine is more addictive. At present, desomorphine is classified as a narcotic drug (DEA code number 9055) in Schedule I of the U.S. Controlled Substances Act and is listed as a controlled substance under the international Single Convention on Narcotic Drugs of 1961.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095233 Sources: http://jpet.aspetjournals.org/content/78/4/375 |
|||
Target ID: CHEMBL233 |
|||
Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28199917 |
|||
Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28199917 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Permonid Approved UseDesomorphine was used for pain relief. |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27372715
Rat: single dose of 20 and 1 mg/kg body weight
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27372715
HepG2 and HepaRG cell lines were incubated with 0.01, 0.1, or 1 mM desomorphine for 3 or 24 h, respectively. The peak area ratio of the desomorphine glucuronide versus codeine-d6 with the highest amount in HepaRG cells incubated with 1 mM desomorphine for 24 h.
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
||
|
DEA NO. |
9055
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB07004MIG
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | |||
|
m1108
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000083172
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | |||
|
207-045-7
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | |||
|
5362456
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | |||
|
3134
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | |||
|
DB01531
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | |||
|
C83663
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | |||
|
8070
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | |||
|
610
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | |||
|
DESOMORPHINE
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | |||
|
7OP86J5E33
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106274
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | |||
|
DTXSID10195390
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY | |||
|
427-00-9
Created by
admin on Mon Mar 31 18:21:59 GMT 2025 , Edited by admin on Mon Mar 31 18:21:59 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)